Work

Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation

Year: 2025

Type: article

Abstract: Claudin 18.2 has emerged as a validated target in solid tumors, spurring next-generation therapies. Bispecific antibodies linking Claudin 18.2 to conditional 4-1BB activation offer a novel approach to enhance T-cell function. By confining costimulation to the tumor microenvironment, they aim to boost efficacy while limiting systemic toxicity. See related article by Ku et al., p. 4944.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-2554

Authors: Giulia Pretelli, Elena Garralda

Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Fundación BBVA, Banco Bilbao Vizcaya Argentaria